Kevan Herold, M.D.

Dr. Herold is a Professor of Immunobiology and Medicine at Yale University. His work in the field of Type 1 diabetes is well known, including his work with Dr. Bluestone that showed the efficacy of anti-CD3 mAb treatment of Type 1 diabetes. His work is translational, bridging the fields of basic immunology, clinical trials, and clinical medicine, which will enable this Program to rapidly move advances in preclinical studies to clinical testing. Much of his recent work pertains to the mechanisms of immune regulation by anti-CD3 mAb in patients, which forms the basis for studies in this Program. He has long standing collaborations with Dr. Bluestone and with Dr. von Herrath. Finally, Dr. Herold is the PI on 3 clinical trials supported by the Immune Tolerance Network, and TrialNet, of which he is an active member.

Research Summary

Dr. Kevan Herold is an Endocrinologist with a special interest in autoimmune diseases and diabetes. He sees adolescent and adult patients with all forms of diabetes and other metabolic disorders. Dr. Herold is conducting research on immunotherapy for treatment of Type 1 diabetes.  Dr. Herold’s laboratory work involves studies of induction of immunologic tolerance to autoimmunity. His current clinical trials are listed below.

Service Activities

2004 – Permanent member, Immunologic Sciences Study Secton, NIH

Assistant: Sandra Barnett
sandra.barnett@yale.edu